record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
accepted
frontiers / frontier
Finding bundle
back to staterecord state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding type[object Object] · [object Object] · [object Object] · [object Object] · [object Object]
evidence
source-boundobservational · manual state transition · Homo sapiens
proof impact
packet context4 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
observational
species
Homo sapiens
evidence spans
APOE4 carrier status increases the importance of ARIA risk stratification for anti-amyloid antibody treatment.
Anti-amyloid antibody labels and trial safety analyses · curator_source · https://www.accessdata.fda.gov/scripts/cder/daf/
conditions
Provenance
source title
Anti-amyloid antibody labels and trial safety analyses
authors
reviewer:will-blair-bot
APOE4 carrier status increases the importance of ARIA risk stratification for anti-amyloid antibody treatment.
vs_21b76b64ce4b5495 · source:Anti-amyloid antibody labels and trial safety analyses|section:curator_source · manual_curation
outgoing
vf_9ded3333a52f3e58genotype-dependent safety context modifies treatment interpretation
incoming
extends · vf_3d254efae19793ea
events
vev_03d96ee7a3a2d7a0finding.caveatedDecision-console scope: ARIA/APOE4 risk is a stratification and monitoring constraint, not a standalone contraindication claim; interpret with current label criteria, MRI monitoring, anticoagulant context, and local eligibility rules.
reviewer:will-blair-bot · 2026-05-06
vev_111c4cd0ae00fa3afinding.caveatedRisk estimates should be read from current labels and trial safety tables before patient-level decisions.
reviewer:will-blair-bot · 2026-05-06
vev_2b4bf0ab6091d328finding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_4b632f2e96853ca3finding.reviewedReviewed for decision-console use: ARIA/APOE4 risk claim is scoped to anti-amyloid antibody monitoring and stratification.
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_49e23f5a2b2007adfinding.reviewReviewed for decision-console use: ARIA/APOE4 risk claim is scoped to anti-amyloid antibody monitoring and stratification.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_6c5189e1748f9542finding.caveatDecision-console scope: ARIA/APOE4 risk is a stratification and monitoring constraint, not a standalone contraindication claim; interpret with current label criteria, MRI monitoring, anticoagulant context, and local eligibility rules.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_7cd889d1f403723bfinding.caveatRisk estimates should be read from current labels and trial safety tables before patient-level decisions.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_c165a37b0cf53a3bfinding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation record targets this finding id.